These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
9. Mechanistic involvement of the calpain-calpastatin system in Alzheimer neuropathology. Higuchi M; Iwata N; Matsuba Y; Takano J; Suemoto T; Maeda J; Ji B; Ono M; Staufenbiel M; Suhara T; Saido TC FASEB J; 2012 Mar; 26(3):1204-17. PubMed ID: 22173972 [TBL] [Abstract][Full Text] [Related]
10. The role of beta-amyloid in the development of Alzheimer's disease. Ii K Drugs Aging; 1995 Aug; 7(2):97-109. PubMed ID: 7579788 [TBL] [Abstract][Full Text] [Related]
11. Recent progress in the characterization of the pathological hallmarks for Alzheimer's disease. Ulrich J Acta Neurol Scand Suppl; 1990; 129():5-7. PubMed ID: 2220325 [No Abstract] [Full Text] [Related]
12. Mutation analysis of the calpastatin gene (CAST) in patients with Alzheimer's disease. Nakayama J; Yoshizawa T; Yamamoto N; Arinami T Neurosci Lett; 2002 Mar; 320(1-2):77-80. PubMed ID: 11849768 [TBL] [Abstract][Full Text] [Related]
13. Cerebrolysin decreases amyloid-beta production by regulating amyloid protein precursor maturation in a transgenic model of Alzheimer's disease. Rockenstein E; Torrance M; Mante M; Adame A; Paulino A; Rose JB; Crews L; Moessler H; Masliah E J Neurosci Res; 2006 May; 83(7):1252-61. PubMed ID: 16511867 [TBL] [Abstract][Full Text] [Related]
14. APP processing and the APP-KPI domain involvement in the amyloid cascade. Menéndez-González M; Pérez-Pinera P; Martínez-Rivera M; Calatayud MT; Blázquez Menes B Neurodegener Dis; 2005; 2(6):277-83. PubMed ID: 16909010 [TBL] [Abstract][Full Text] [Related]
15. Calpain mediates calcium-induced activation of the erk1,2 MAPK pathway and cytoskeletal phosphorylation in neurons: relevance to Alzheimer's disease. Veeranna ; Kaji T; Boland B; Odrljin T; Mohan P; Basavarajappa BS; Peterhoff C; Cataldo A; Rudnicki A; Amin N; Li BS; Pant HC; Hungund BL; Arancio O; Nixon RA Am J Pathol; 2004 Sep; 165(3):795-805. PubMed ID: 15331404 [TBL] [Abstract][Full Text] [Related]
17. Toward the characterization and identification of gamma-secretases using transition-state analogue inhibitors. Moore CL; Diehl TS; Selkoe DJ; Wolfe MS Ann N Y Acad Sci; 2000; 920():197-205. PubMed ID: 11193150 [TBL] [Abstract][Full Text] [Related]
18. Calpain inhibitor A-705253 mitigates Alzheimer's disease-like pathology and cognitive decline in aged 3xTgAD mice. Medeiros R; Kitazawa M; Chabrier MA; Cheng D; Baglietto-Vargas D; Kling A; Moeller A; Green KN; LaFerla FM Am J Pathol; 2012 Aug; 181(2):616-25. PubMed ID: 22688056 [TBL] [Abstract][Full Text] [Related]
19. Molecular and genetic investigations on Alzheimer brain amyloid. Majocha RE; Marotta CA J Geriatr Psychiatry Neurol; 1988; 1(2):65-70. PubMed ID: 3075493 [TBL] [Abstract][Full Text] [Related]
20. Amyloid beta peptide load is correlated with increased beta-secretase activity in sporadic Alzheimer's disease patients. Li R; Lindholm K; Yang LB; Yue X; Citron M; Yan R; Beach T; Sue L; Sabbagh M; Cai H; Wong P; Price D; Shen Y Proc Natl Acad Sci U S A; 2004 Mar; 101(10):3632-7. PubMed ID: 14978286 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]